← Back to patent-cliff list
Kamuvudines
Tier C — Watch / tradeKamuvudines
Inflammasome Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Inflammasomes, NLRP3, RT
Indications (approved)：地图状萎缩, 年龄相关性黄斑变性
Regional status
US
Phase II
2023-11-13
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Kamuvudines?
Approved indications include: 地图状萎缩, 年龄相关性黄斑变性.
When does the Kamuvudines patent expire?
No public expiry year is available for Kamuvudines yet; this page updates once verified.
How do I get a quote for Kamuvudines intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02